Cardlytics, Inc.

Case Overview
32 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 03/25/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: Cardlytics, Inc. |
Court: | Court: Northern District of Georgia |
Case Number: | Case Number: 1:25cv00279 |
Class Period: | Class Period: 03/14/2024 - 08/07/2024 |
Ticker: | Ticker: CDLX |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of Georgia on behalf of those who acquired Cardlytics, Inc. (“Cardlytics” or the “Company”) (NASDAQ:CDLX) securities during the period through March 14, 2024, through August 7, 2024 (“the Class Period”). Investors have until March 25, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On May 8, 2024, after the market closed, Cardlytics revealed that its first quarter 2024 revenue only increased 8% year-over-year, despite a 12% increase in billings, due to a 20.2% increase in consume incentives. On this news, the price of Cardlytics shares declined by $5.33 per share, or approximately 36.5%, from $14.60 per share on May 8, 2024, to close at $9.27 on May 9, 2024.
Then, on August 7, 2024, after the market closed, Cardlytics released its second quarter 2024 financial results, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million. The press release also disclosed that Karim Temsamani had stepped down as Chief Executive Officer and from the Board of Directors. On this news, the price of Cardlytics shares declined by $3.94 per share, or approximately 57.1%, from $6.90 per share on August 7, 2024, to close at $2.96 on August 8. 2024.
The complaint alleges that defendants, throughout the Class Period, failed to disclose to investors that: (1) increasing consumer engagement led to an increase in consumer incentives; (2) that the Company could not increase its billings commensurate with the increased consumer engagement; (3) that, as a result, there was a significant risk that its revenue growth would slow or decline; and (4) that the changes to ADE, which led to increased consumer engagement, led to the “under-delivery” of budgets and customers billing estimates.
On May 8, 2024, after the market closed, Cardlytics revealed that its first quarter 2024 revenue only increased 8% year-over-year, despite a 12% increase in billings, due to a 20.2% increase in consume incentives. On this news, the price of Cardlytics shares declined by $5.33 per share, or approximately 36.5%, from $14.60 per share on May 8, 2024, to close at $9.27 on May 9, 2024.
Then, on August 7, 2024, after the market closed, Cardlytics released its second quarter 2024 financial results, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million. The press release also disclosed that Karim Temsamani had stepped down as Chief Executive Officer and from the Board of Directors. On this news, the price of Cardlytics shares declined by $3.94 per share, or approximately 57.1%, from $6.90 per share on August 7, 2024, to close at $2.96 on August 8. 2024.
The complaint alleges that defendants, throughout the Class Period, failed to disclose to investors that: (1) increasing consumer engagement led to an increase in consumer incentives; (2) that the Company could not increase its billings commensurate with the increased consumer engagement; (3) that, as a result, there was a significant risk that its revenue growth would slow or decline; and (4) that the changes to ADE, which led to increased consumer engagement, led to the “under-delivery” of budgets and customers billing estimates.